Literature DB >> 25888358

Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?

Piotr Obara1, Haiping Liu, Kristen Wroblewski, Chen-Peng Zhang, Peng Hou, Yulei Jiang, Ping Chen, Yonglin Pu.   

Abstract

PURPOSE: Metabolic tumor burden (MTB) measurements including metabolic tumor volume and total lesion glycolysis have been shown to have prognostic value in non-small-cell lung cancer (NSCLC). The calculation of MTB typically utilizes software to semiautomatically draw volumes of interest around the tumor, which are subsequently manually adjusted by the radiologist to include the entire tumor. The manual adjustment step can be time-consuming and observer-dependent. We compared the agreement of MTB values obtained using the semiautomatic method with and without manual adjustment in NSCLC patients.
METHODS: This IRB-approved prospective study included 134 patients with histologically proven NSCLC who underwent fluorine-18 fluorodeoxyglucose PET/computed tomography. The MTB of the primary tumor was measured with a semiautomatic gradient-based method without manual adjustment (the semiautomatic gradient method) and with manual adjustment (the manually adjusted semiautomatic gradient method) by two radiologists using the MIM PETedge tool. The paired t-test, Wilcoxon signed-rank test, and concordance correlation coefficient (CCC) were calculated to evaluate the agreement between MTB measures obtained with these two methods, as well as agreement between the two radiologists for each method.
RESULTS: Maximum standardized uptake value was identical between the two methods. No statistically significant difference was present for peak standardized uptake value, metabolic tumor volume, and total lesion glycolysis values between the two methods (P=0.23, 0.45, and 0.37, respectively). Excellent agreement between the two methods was found in terms of CCC (CCC>0.98 for all measures). Interobserver reliability was excellent for all measures (CCC>0.90).
CONCLUSION: The semiautomatic gradient-based tumor-segmentation method can be used without the additional manual adjustment step for MTB quantification of primary NSCLC tumors.

Entities:  

Mesh:

Year:  2015        PMID: 25888358      PMCID: PMC6069606          DOI: 10.1097/MNM.0000000000000317

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  46 in total

1.  A novel PET tumor delineation method based on adaptive region-growing and dual-front active contours.

Authors:  Hua Li; Wade L Thorstad; Kenneth J Biehl; Richard Laforest; Yi Su; Kooresh I Shoghi; Eric D Donnelly; Daniel A Low; Wei Lu
Journal:  Med Phys       Date:  2008-08       Impact factor: 4.071

2.  PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?

Authors:  Kailiang Wu; Yee C Ung; Jennifer Hornby; Marc Freeman; David Hwang; Ming S Tsao; Max Dahele; Gail Darling; Donna E Maziak; Romeo Tirona; Kathy Mah; C Shun Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

3.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

4.  A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET.

Authors:  Saoussen Belhassen; Habib Zaidi
Journal:  Med Phys       Date:  2010-03       Impact factor: 4.071

5.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

6.  Feasibility study of FDG PET/CT-derived primary tumour glycolysis as a prognostic indicator of survival in patients with non-small-cell lung cancer.

Authors:  G Mehta; A Chander; C Huang; M Kelly; P Fielding
Journal:  Clin Radiol       Date:  2013-12-05       Impact factor: 2.350

7.  Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.

Authors:  F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff
Journal:  Nuklearmedizin       Date:  2011-10-26       Impact factor: 1.379

8.  Defining a radiotherapy target with positron emission tomography.

Authors:  Quinten C Black; Inga S Grills; Larry L Kestin; Ching-Yee O Wong; John W Wong; Alvaro A Martinez; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

9.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

10.  Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Authors:  Zachary D Horne; David A Clump; John A Vargo; Samir Shah; Sushil Beriwal; Steven A Burton; Annette E Quinn; Matthew J Schuchert; Rodney J Landreneau; Neil A Christie; James D Luketich; Dwight E Heron
Journal:  Radiat Oncol       Date:  2014-01-30       Impact factor: 3.481

View more
  9 in total

1.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

2.  Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.

Authors:  Yonglin Pu; James X Zhang; Haiyan Liu; Daniel Appelbaum; Jianfeng Meng; Bill C Penney
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-07       Impact factor: 9.236

3.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

4.  Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.

Authors:  Xuee Zhu; Chuanhong Liao; Bill C Penney; Feng Li; Mark K Ferguson; Cassie A Simon; Tianming Wu; Haiyan Liu; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2017-02       Impact factor: 1.690

Review 5.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Authors:  Hyung-Jun Im; Tyler Bradshaw; Meiyappan Solaiyappan; Steve Y Cho
Journal:  Nucl Med Mol Imaging       Date:  2017-09-19

6.  Chordoma: 18F-FDG PET/CT and MRI imaging features.

Authors:  Joshua T Olson; Doris E Wenger; Peter S Rose; Ivy A Petersen; Stephen M Broski
Journal:  Skeletal Radiol       Date:  2021-02-01       Impact factor: 2.199

7.  Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.

Authors:  Haiping Liu; Ping Chen; Kristen Wroblewski; Peng Hou; Chen-Peng Zhang; Yulei Jiang; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2016-01       Impact factor: 1.690

Review 8.  Challenges in the target volume definition of lung cancer radiotherapy.

Authors:  Susan Mercieca; José S A Belderbos; Marcel van Herk
Journal:  Transl Lung Cancer Res       Date:  2021-04

9.  Accurate FDG PET tumor segmentation using the peritumoral halo layer method: a study in patients with esophageal squamous cell carcinoma.

Authors:  Sungmin Jun; Jung Gu Park; Youngduk Seo
Journal:  Cancer Imaging       Date:  2018-09-26       Impact factor: 3.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.